Diagnostic performance of plasma biomarkers for Alzheimer's disease using a fully automated platform: A real-world clinical study
Journal of Alzheimer s Disease,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 26, 2025
This
study
evaluated
the
diagnostic
performance
of
plasma
biomarkers
for
Alzheimer's
disease
(AD)
using
an
automated
platform.
In
a
cohort
74
consecutive
patients,
p-Tau181
levels
were
significantly
higher
in
AD
compared
to
non-AD
groups
and
showed
correlation
with
cerebrospinal
fluid
biomarkers.
Plasma
demonstrated
high
accuracy
AD,
area
under
curve
0.854.
The
findings
suggest
that
biomarkers,
particularly
p-Tau181,
could
improve
accessibility
efficiency
diagnostics
clinical
settings,
offering
less
invasive
cost-effective
alternative
traditional
methods.
Язык: Английский
Reproducibility of Plasma Biomarker Measurements Across Laboratories: Insights Into ptau217, GFAP, and NfL
Dementia and Neurocognitive Disorders,
Год журнала:
2025,
Номер
24(2), С. 91 - 91
Опубликована: Янв. 1, 2025
Plasma
biomarkers,
including
phosphorylated
tau
(ptau217),
glial
fibrillary
acidic
protein
(GFAP),
and
neurofilament
light
chain
(NfL),
are
promising
tools
for
detecting
Alzheimer's
disease
(AD)
pathology.
However,
cross-laboratory
reproducibility
remains
a
challenge,
even
when
using
identical
analytical
platforms
such
as
single-molecule
array
(Simoa).
This
study
aimed
to
compare
plasma
biomarker
measurements
(ptau217,
GFAP,
NfL)
between
2
laboratories,
the
University
of
Gothenburg
(UGOT)
DNAlink,
evaluate
their
associations
with
amyloid
positron
emission
tomography
(PET)
imaging.
biomarkers
were
measured
Simoa
at
both
laboratories:
UGOT
DNAlink
Incorporation.
Diagnostic
performance
predicting
PET
positivity,
agreement,
impact
normalization
techniques
assessed.
Bland-Altman
plots
correlation
analyses
employed
agreement
variability.
ptau217
concentrations
exhibited
strong
correlations
global
centiloid
values,
comparable
diagnostic
laboratories
(area
under
curve=0.94
0.95
DNAlink).
Cross-laboratory
was
excellent
(r=0.96),
improving
further
after
natural
log
transformation.
GFAP
NfL
also
demonstrated
moderate
(r=0.86
r=0.99
NfL),
reducing
consistent
across
platforms,
improved
normalization.
These
findings
support
scalability
multi-center
studies
underscore
potential
standardized
applications
in
AD
research
clinical
practice.
Язык: Английский
Advances in blood‐based phosphorylated tau protein biomarkers and their detection technology for Alzheimer's disease
Shi-Yuan Fu,
Qiaoping Zheng,
Beihui Xu
и другие.
View,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 12, 2025
Abstract
Alzheimer's
disease
(AD)
is
a
prevalent
neurodegenerative
disorder
characterized
primarily
by
memory
loss
and
impaired
cognitive
function.
With
the
aging
world
population,
incidence
of
AD
rising,
imposing
substantial
medical
economic
burdens
on
society.
Current
diagnostic
methods
for
predominantly
rely
imaging
studies
cerebrospinal
fluid
analysis,
which
has
limitations
such
as
complex
operation
high
costs.
Therefore,
development
minimally
invasive,
convenient,
accessible
blood‐based
biomarkers
become
research
hotspot.
Phosphorylated
tau
protein
(p‐tau)
plays
crucial
role
in
AD,
its
abnormal
phosphorylation
closely
related
to
pathogenesis
disease.
This
paper
highlights
potential
applications
three
specific
phosphorylated
proteins—p‐tau217,
p‐tau181,
p‐tau231—in
early
diagnosis,
differential
progression
monitoring
aiming
provide
reference
future
clinical
applications.
Furthermore,
reviews
advancements
various
ultrasensitive
detection
technologies
p‐tau
measurement.
The
application
these
significantly
enhanced
sensitivity
specificity
detection,
making
it
feasible
detect
low
concentrations
blood
proteins,
thereby
advancing
diagnosis
AD.
Язык: Английский
Associations Between Free and Cued Selective Reminding Test and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment
Journal of Alzheimer s Disease,
Год журнала:
2024,
Номер
100(2), С. 713 - 723
Опубликована: Июнь 21, 2024
Background:
The
Free
and
Cued
Selective
Reminding
Test
(FCSRT),
assessing
verbal
episodic
memory
with
controlled
learning
semantic
cueing,
has
been
recommended
for
detecting
the
genuine
encoding
storage
deficits
characterizing
AD-related
disorders.
Objective:
present
study
aims
at
investigating
ability
of
FCSRT
in
predicting
cerebrospinal
fluid
(CSF)
evidence
amyloid-β
positivity
subjects
amnestic
mild
cognitive
impairment
(aMCI)
exploring
its
associations
amyloidopathy,
tauopathy
neurodegeneration
biomarkers.
Methods:
120
aMCI
underwent
comprehensive
neurological
neuropsychological
examinations,
including
assessment,
CSF
collection;
Aβ42/40
ratio,
p-tau181,
total-tau
quantification
were
conducted
by
an
automated
CLEIA
method
on
Lumipulse
G1200.
Based
ratio
value,
classified
as
either
A+
or
A–.
Results:
All
subitem
scores
significantly
lower
group
predicted
status,
Immediate
Total
Recall
(ITR)
being
best
predictor.
No
significant
correlations
found
between
biomarkers
A–
group,
while
all
negatively
correlated
p-tau181
total-tau,
but
not
ratio.
Conclusions:
confirms
validity
a
tool
diagnosis
AD,
able
to
predict
presence
deposition
high
specificity.
p-tau-181
levels
due
AD
could
further
encourage
clinical
use
this
simple
cost-effective
test
evaluation
individuals
aMCI.
Язык: Английский